Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA4 | P22748 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26082964 | 0.93 | SMN1; SMN2 (0.45) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL18908729 | 0.93 | KMT2A (0.57) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL22054928 | 0.93 | KMT2A (0.57) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL23665082 | 0.93 | KMT2A (0.57) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL18908667 | 0.93 | KMT2A (0.57) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL16674308 | 0.91 | KMT2A (0.53) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL25118082 | 0.86 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL24811372 | 0.86 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL24812501 | 0.86 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2TP53HPGD | |
| SCHEMBL24811371 | 0.86 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119416-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-20210221826-A1 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| US-10913752-B2 | Bivalent bromodomain inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200172553-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| WO-2017091673-A2 | BIVALENT BROMODOMAIN INHIBTORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221826-A1 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BET1, BRD2 | KMT2A 401/4885MEN1 3404/4885SMN1; SMN2 3934/4885 |
| US-10913752-B2 | Bivalent bromodomain inhibitors and uses thereof | BRD4, BRD2, BET1 | KMT2A 406/4885MEN1 3402/4885SMN1; SMN2 3861/4885 |
| US-20200172553-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BET1, BRD2 | KMT2A 477/4885MEN1 3377/4885SMN1; SMN2 3865/4885 |
| US-20220119416-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BET1, BRD2 | KMT2A 401/4885MEN1 3404/4885SMN1; SMN2 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.